4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q2 EPS of ($1.04), $0.03 worse than the analyst estimate of ($1.01). Revenue for the quarter came in at $3.78 million versus the consensus estimate of $2.66 million.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.